Optimizing the purification and analysis of miRNAs from urinary exosomes

Channavajjhala, Sarath Kiran; Rossato, Marzia; Morandini, Francesca; Castagna, Annalisa; Pizzolo, Francesca; Bazzoni, Flavia; Olivieri, Oliviero

doi:10.1515/cclm-2013-0562

Cited by 54 publications

(44 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are also differences in the results obtained in relation to the method used for isolating total RNA from different body fluids (mirVana, Exiqon miRCURY, miRNeasy, TRIzol) [14,[33][34][35]. Unfortunately, results published in these studies do not always support similar conclusions.…”

Section: Preanalytical and Analytical Variables In Mirna Measurementmentioning

confidence: 85%

miRNAs as novel biomarkers in the management of prostate cancer

Filella

Foj

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

100

View full text Add to dashboard Cite

microRNAs (miRNAs) are small non-coding RNAs that control gene expression posttranscriptionally and are part of the giant non codifying genoma. Cumulating data suggest that miRNAs are promising potential biomarkers for many diseases, including cancer. Prostate cancer (PCa) detection is currently based in the serum prostate-specific antigen biomarker and digital rectal examination. However, these methods are limited by a low predictive value and the adverse consequences associated with overdiagnosis and overtreatment. New biomarkers that could be used for PCa detection and prognosis are still needed. Recent studies have demonstrated that aberrant expressions of microRNAs are associated with the underlying mechanisms of PCa. This review attempts to extensively summarize the current knowledge of miRNA expression patterns, as well as their targets and involvement in PCa pathogenesis. We focused our review in the value of circulating and urine miRNAs as biomarkers in PCa patients, highlighting the existing discrepancies between different studies, probably associated with the important methodological issues related to their quantitation and normalization. The majority of studies have been performed in serum or plasma, but urine obtained after prostate massage appears as a new way to explore the usefulness of miRNAs. Large screening studies to select a miRNA profile have been completed, but bioinformatics tools appear as a new approach to select miRNAs that are relevant in PCa development.Promising preliminary results were published concerning miR-141, miR-375 and miR-21, but larger and prospective studies using standardized methodology are necessary to define the value of miRNAs in the detection and prognosis of PCa.

show abstract

Section: Preanalytical and Analytical Variables In Mirna Measurementmentioning

confidence: 85%

miRNAs as novel biomarkers in the management of prostate cancer

Filella

Foj

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

100

View full text Add to dashboard Cite

show abstract

“…26 Subsequently, the sample was passed through a 0.45 mm pore size Millipore Hydrophilic Durapore filter (Merck Millipore, Tokyo, Japan). 27,28 The largersized microvesicular particles were deposited onto the filter membrane. The resulting filtrate was transferred to a sterile vessel, and the appropriate volume of ExoQuick-TC was added.…”

Section: Ev Preparationmentioning

confidence: 99%

Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms

et al. 2016

View full text Add to dashboard Cite

“…Extensive efforts in the development and optimization of assays for the isolation, quantification, and characterization of cancer- or organ-specific EVs from body fluids are ongoing [109–123]. EV RNA isolation protocols and novel approaches to the detection of RNA from EV samples are also continuously improving [124–128]. …”

Section: Ncrnas As Biomarkers For the Minimally Invasive Management Omentioning

confidence: 99%

The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice

et al. 2017

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common type of cancer and the second leading cause of cancer-related death in men. Despite extensive research, the molecular mechanisms underlying PCa initiation and progression remain unclear, and there is increasing need of better biomarkers that can distinguish indolent from aggressive and life-threatening disease. With the advent of advanced genomic technologies in the last decade, it became apparent that the human genome encodes tens of thousands non-protein-coding RNAs (ncRNAs) with yet to be discovered function. It is clear now that the majority of ncRNAs exhibit highly specific expression patterns restricted to certain tissues and organs or developmental stages and that the expression of many ncRNAs is altered in disease and cancer, including cancer of the prostate. Such ncRNAs can serve as important biomarkers for PCa diagnosis, prognosis, or prediction of therapy response. In this review, we give an overview of the different types of ncRNAs and their function, describe ncRNAs relevant for the diagnosis and prognosis of PCa, and present emerging new aspects of ncRNA research that may contribute to the future utilization of ncRNAs as clinically useful therapeutic targets.

show abstract

Optimizing the purification and analysis of miRNAs from urinary exosomes

Cited by 54 publications

References 40 publications

miRNAs as novel biomarkers in the management of prostate cancer

miRNAs as novel biomarkers in the management of prostate cancer

Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms

The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice

Contact Info

Product

Resources

About